ArticleClinical ophthalmology (Auckland, N.Z.)2026
Short-Term Changes in Persistent Ocular Discomfort After Add-On Motugivatrep in Patients with Dry Eye Disease: A Retrospective Observational Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate whether motugivatrep improves persistent ocular discomfort in patients with dry eye disease who remain symptomatic despite ongoing conventional treatment. Patients and Methods: This retrospective observational study included 41 eyes from 23 patients with dry eye disease who experienced persistent ocular discomfort for more than 2 months despite standard dry eye therapy, as defined by an Ocular Surface Disease Index (OSDI) total score of ≥13. A 0.3% motugivatrep ophthalmic solution was added to their existing treatment regimen. Subjective symptoms and objective ocular surface findings were assessed before treatment and 2 weeks after initiation. The primary outcome was a change in the total OSDI score. The secondary outcomes included changes in individual OSDI symptom items, fluorescein ocular surface staining scores, and tear film breakup time. Results: The OSDI total score significantly decreased from 44.9 ± 25.3 at baseline to 25.5 ± 21.9 at 2 weeks, with a mean paired change of -19.4 points (95% CI, -27.3 to -11.6; n=23; Wilcoxon signed-rank test, p = 1.8×10 Conclusion: Add-on motugivatrep was associated with an improvement in residual subjective ocular discomfort in patients with dry eye disease despite conventional therapy and may be a useful adjunctive treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.